Live, Hybrid Conference | 1 Cat. 1
Thursday, April 16, 2026 | 5:30 p.m. - 7:30 p.m.
Baptist Hospital, 5 MCVI Conference Room / Zoom
Cardiac amyloidosis is an increasingly recognized and treatable cause of heart failure and cardiomyopathy. Advances in imaging, biomarkers, and targeted therapies have transformed how this condition is diagnosed and managed, making early recognition more important than ever.
Lawrence Blacher, MD
Please join us to hear Omar F. Abou-Ezzeddine, M.D.C.M., M.S., at the Lawrence Blacher, M.D., Memorial Lecture, where he will provide a 2026 update on amyloid cardiomyopathy, highlighting current diagnostic strategies, emerging therapies, and practical approaches to patient care.
Learning Objectives
Upon completion of this conference, participants should be better able to:
- Describe current and emerging diagnostic and imaging strategies in the diagnosis of amyloid cardiomyopathy.
- Apply supportive management strategies for the care of patients with amyloid cardiomyopathy.
- Evaluate current and emerging disease-modifying therapies for amyloid cardiomyopathy.
